Abstract
Currently, three inhibitors of HIV-I protease are showing promise in clinical use against HIV infection. However, the development of resistance continues to be an important consideration in protease inhibitor therapy. Mutations in protease which lead to resistance have been observed in both inhibitor treated and untreated individuals (Borman et al., 1996; Condra et al., 1995). Variations have also been observed to a higher degree in areas of the gag region including p7, and the cleavage site sequences (Barrie et al., 1996).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Barrie, K. A., Perez, E., Lamers, S., Farmerie, W., Dunn, B., Sleasman, J., Goodenow, M. 1996 Virology 219:407–416.
Borman, A., Paulous, S., Clavel, F. 1996 J. Gen. Virol. 77:419–426.
Condra, J., Schleif, W., Blahy, O., Gabryelski, L., Graham, D., Quintero, J., Rhodes, A., Robbins, H., Roth, E., Shivaprakash, M., Titus, D., Yang, T., Toppler, H., Squires, K., Deutsch, P., Eminl, E. 1995 Nature 374:569–571
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bloom, G. et al. (1998). A Comparison of gag—pol Precursor Cleavage in Naturally Arising HIV Variants. In: James, M.N.G. (eds) Aspartic Proteinases. Advances in Experimental Medicine and Biology, vol 436. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5373-1_7
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5373-1_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7452-7
Online ISBN: 978-1-4615-5373-1
eBook Packages: Springer Book Archive